Relay Therapeutics (RLAY) Competitors $3.62 +0.02 (+0.56%) Closing price 07/3/2025 02:34 PM EasternExtended Trading$3.62 0.00 (0.00%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. GMTX, IBRX, TWST, ARWR, APLS, VCEL, RXRX, NAMS, DNLI, and KNSAShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Its Competitors Gemini Therapeutics ImmunityBio Twist Bioscience Arrowhead Pharmaceuticals Apellis Pharmaceuticals Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Gemini Therapeutics (NASDAQ:GMTX) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk. Do insiders and institutionals believe in GMTX or RLAY? 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, GMTX or RLAY? Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Which has preferable valuation and earnings, GMTX or RLAY? Gemini Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-54.75Relay Therapeutics$7.68M80.82-$337.71M-$2.23-1.62 Is GMTX or RLAY more profitable? Gemini Therapeutics' return on equity of -38.78% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Relay Therapeutics N/A -44.17%-39.53% Does the media refer more to GMTX or RLAY? In the previous week, Relay Therapeutics had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Relay Therapeutics and 0 mentions for Gemini Therapeutics. Relay Therapeutics' average media sentiment score of 1.02 beat Gemini Therapeutics' score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral Relay Therapeutics Positive Do analysts rate GMTX or RLAY? Relay Therapeutics has a consensus price target of $17.67, indicating a potential upside of 388.03%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryRelay Therapeutics beats Gemini Therapeutics on 9 of the 14 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$622.35M$2.43B$5.56B$9.03BDividend YieldN/A1.67%5.22%3.99%P/E Ratio-1.629.3527.6920.25Price / Sales80.82478.02389.63163.10Price / CashN/A158.5936.8958.10Price / Book0.784.588.035.67Net Income-$337.71M$31.34M$3.18B$249.21M7 Day Performance9.70%3.25%2.93%3.28%1 Month Performance7.74%3.46%1.72%3.95%1 Year Performance-43.08%0.77%34.39%20.98% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.8025 of 5 stars$3.62+0.6%$17.67+388.0%-43.1%$622.35M$7.68M-1.62330Positive NewsGMTXGemini TherapeuticsN/A$54.50+0.7%N/A+23.2%$2.36BN/A-54.5030High Trading VolumeIBRXImmunityBio1.8512 of 5 stars$2.64-2.2%$12.25+364.0%-57.5%$2.33B$14.74M-4.55590Negative NewsGap UpTWSTTwist Bioscience4.4645 of 5 stars$36.79+2.4%$50.40+37.0%-21.4%$2.20B$312.97M-11.32990Positive NewsARWRArrowhead Pharmaceuticals3.9445 of 5 stars$15.80-1.7%$43.71+176.7%-34.4%$2.18B$3.55M-11.29400APLSApellis Pharmaceuticals4.4269 of 5 stars$17.31-0.7%$40.05+131.4%-50.4%$2.18B$781.37M-9.67770Trending NewsAnalyst ForecastAnalyst RevisionVCELVericel2.845 of 5 stars$42.55+2.0%$61.14+43.7%-10.5%$2.14B$237.22M1,418.81300News CoveragePositive NewsRXRXRecursion Pharmaceuticals1.9172 of 5 stars$5.06+0.6%$7.00+38.3%-28.1%$2.06B$58.84M-2.86400Analyst ForecastNAMSNewAmsterdam Pharma2.2796 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.03B$45.56M-9.634Positive NewsAnalyst UpgradeDNLIDenali Therapeutics4.6373 of 5 stars$13.99-0.8%$33.71+141.0%-30.5%$2.03BN/A-5.24430Positive NewsKNSAKiniksa Pharmaceuticals International3.275 of 5 stars$27.67-1.3%$38.80+40.2%+43.9%$2.02B$423.24M-110.68220Analyst Upgrade Related Companies and Tools Related Companies GMTX Alternatives IBRX Alternatives TWST Alternatives ARWR Alternatives APLS Alternatives VCEL Alternatives RXRX Alternatives NAMS Alternatives DNLI Alternatives KNSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s BIGGEST setup yet.After another undefeated quarter, “Market Wizard” Larry Benedict is sounding the alarm on a $194 trillion mark...Brownstone Research | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
